Insiders Trades
Colgate Palmolive Co Stock: price and insider trades · United States
Colgate Palmolive Co: what insiders have been doing
Every trade that managers of Colgate Palmolive Co disclose to SEC (Form 4) is tracked on this page. The company sits in the Retail & Commerce sector and is based in New York City, United States. It was founded in 1806. In the past year (18 October 2025 to 18 October 2026), 74 filings came from 17 insiders.
All open-market trades in the period are sales: 6 sales worth €30.6M, by 4 insiders, with no purchase on record. Biggest ticket of the year: €12.9M, sold by Wallace Noel R. and made public on 6 August 2026 (0.021% of market cap).
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,810 companies, median 19 filings), a count of 74 filings is above the norm. The full history, which starts in 2016, counts no purchases against 32 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 20.38 bn USD and net income at 2.13 bn USD, and the dividend at 2.08 USD per share.
In the same sector, recent insider purchases at GameStop Corp. and Celsius Holdings, Inc. also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
378
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€38M
32 ops. · all time
Who traded when
BuySaleNoel R. Wallace4 sales
Sally Massey3 sales
Panagiotis Tsourapas2 sales
Gregory Malcolm1 sale
John T. Cahill1 sale
Analyst consensus: bullish or bearish?
Analysts rate Colgate Palmolive Co Buy (bullish), based on 20 analysts. Average price target: US$98.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,011 of 24,148 companies
59.9
score / 100
Value45
Quality74
FCF yld4.8%
Earn yld2.8%
EV/EBITDA21.1x
ROE267%
Gross mgn60%
Net mgn10%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$89.95
Analyst consensus
20 analystsBuy
US$87.00Target US$98.25(+9%)US$110.00
Income statement
RevenueUS$20.4B
Gross profitUS$12.3B60% margin
EBITDAUS$4B19% margin
Net incomeUS$2.1B9.7% margin
Valuation
PER (trailing)35.4x
PER (forward)22.0x
P/Book303.9x
Beta0.32
Balance sheet & cash
Market capUS$71.7B
Total debtUS$8.6B
Free Cash FlowUS$3.6B
Debt / Equity1388%
Profitability & ownership
ROE267.4%
ROA15.8%
% insiders0.2%
% institutions86.3%
Last declaration on 2 October 2026
Declarations378 total
214 shares@ US$87.420.0000% mcap9.8% of flowCommon StockSEC:0001225208-26-008101:0
300 shares@ US$87.420.0000% mcap1.4% of flowCommon StockSEC:0001225208-26-008102:0
271 shares@ US$87.420.0000% mcap1.2% of flowCommon StockSEC:0001225208-26-008100:0
3,908 shares0Common StockSEC:0001225208-26-007884:0
8,045 shares0Common StockSEC:0001225208-26-007885:0
1,081 shares0Common StockSEC:0001225208-26-007881:0
2,207 shares0Common StockSEC:0001225208-26-007882:0
3,333 shares0Common StockSEC:0001225208-26-007883:0
4,597 shares0Common StockSEC:0001225208-26-007886:0
7,355 shares0Common StockSEC:0001225208-26-007887:0
29,649 shares0Common StockSEC:0001225208-26-007888:0
404 shares@ US$86.800.0001% mcap33.4% of flowCommon StockSEC:0001225208-26-007825:0
331 shares@ US$86.800.0000% mcap27.4% of flowCommon StockSEC:0001225208-26-007825:1
472 shares@ US$86.800.0001% mcap39.2% of flowCommon StockSEC:0001225208-26-007825:2
622 shares@ US$86.800.0001% mcap100.0% of flowCommon StockSEC:0001225208-26-007826:0
649 shares@ US$86.800.0001% mcap3.2% of flowCommon StockSEC:0001225208-26-007827:0
439 shares@ US$86.800.0001% mcap2.2% of flowCommon StockSEC:0001225208-26-007827:1
499 shares@ US$86.800.0001% mcap2.5% of flowCommon StockSEC:0001225208-26-007827:2
167 shares@ US$86.800.0000% mcap0.5% of flowCommon StockSEC:0001225208-26-007828:0
151 shares@ US$86.800.0000% mcap0.4% of flowCommon StockSEC:0001225208-26-007828:1
225 shares@ US$86.800.0000% mcap0.6% of flowCommon StockSEC:0001225208-26-007828:2
651 shares@ US$86.800.0001% mcap0.7% of flowCommon StockSEC:0001225208-26-007829:0
459 shares@ US$86.800.0001% mcap0.5% of flowCommon StockSEC:0001225208-26-007829:1
686 shares@ US$86.800.0001% mcap0.7% of flowCommon StockSEC:0001225208-26-007829:2
1,197 shares@ US$86.800.0001% mcap0.6% of flowCommon StockSEC:0001225208-26-007830:0
25 of 378 declarations
About Colgate Palmolive Co
Colgate-Palmolive Company (ticker: CL) is a large-cap consumer staples company listed in the United States on the NYSE (New York Stock Exchange). For French-, Belgian- and Swiss-based investors, it is best understood as a global defensive franchise in everyday consumer goods, with demand tied to recurring household spending rather than economic cycles. The company traces its roots back to 1806, when William Colgate founded the original business, and over time it evolved through expansion and acquisitions into one of the world’s best-known oral care and personal care groups. Its headquarters are in New York, United States.
Colgate-Palmolive’s operations are centered on two main segments: Oral, Personal and Home Care, and Pet Nutrition. The first segment includes oral hygiene, personal care and home care products. Its global brand portfolio includes Colgate, Palmolive, Darlie, elmex, meridol, hello, Protex, Sanex, Softsoap, Speed Stick, Ajax, Fabuloso and Suavitel, among others. The second segment is built around Hill’s Science Diet and Hill’s Prescription Diet, premium pet nutrition brands that provide an attractive source of diversification beyond the company’s historic toothpaste and toothbrush franchise.
Read moreShow less
From a competitive standpoint, Colgate-Palmolive enjoys strong brand equity, broad international reach and a high level of recurring consumption across its categories. In oral care, it is one of the most recognized names globally and has particularly deep penetration in emerging markets. The company sells in more than 200 countries and territories, giving it geographic diversification that is unusually broad for a consumer staples company. Its footprint spans North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Recent developments in 2025 indicate continued operational execution, with management emphasizing growth, margin discipline, productivity initiatives and ongoing investment in brands and innovation. The company also continues to highlight sustainability and social impact priorities, which remain part of its long-term corporate strategy. For equity investors, CL stands out as a high-quality, cash-generative consumer defensive name with resilient demand characteristics, while still being exposed to foreign exchange movements, competitive pricing pressure and global category dynamics.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
